

PRESS RELEASE

Temedica announces cooperation with Bristol Myers Squibb for the development of a digital companion for psoriasis patients

- The app will be available to all psoriasis patients in Germany
- Approximately 2 million Germans are affected by psoriasis
- Improved patient support along their entire disease journey

Munich, Germany, March 15, 2022 – Temedica GmbH, a leading digital health and health insights company, today announced its cooperation with Bristol Myers Squibb to develop a digital companion for patients with psoriasis. The app will support patients along their entire patient journey, helping them to better manage their disease. Psoriasis affects approximately 2 million people in Germany and is one of the most common chronic inflammatory skin diseases. No curative treatments currently exist, leaving patients with the burden of controlling symptoms through a variety of prescriptions to the best of their ability.¹

Gloria Seibert, Founder & Chief Executive Officer at Temedica, said:

"We are proud to announce the development of another patient companion evolving from Temedica's App Platform Technology and our first one in cooperation with Bristol Myers Squibb. Psoriasis affects each patient differently, so we integrate the advice of patients as well as healthcare professionals in designing a digital companion that meets the patients' needs. Our vision at Temedica is 'crafting the future of personal health'. This digital companion for psoriasis patients is an important milestone on this path."

Dr. Michael May, Medical Director at Bristol Myers Squibb, Germany, said:

"We are happy to support the development of an innovative digital patient companion. Engaging in digital health is part of our goal to make an impact on the lives of patients with serious diseases, ultimately transforming patients' experiences through science. Insights into the specific experiences with the disease can help us to learn more about the needs of those affected. This can be useful in developing new treatment options and support for those living with psoriasis."

The digital companion will enable psoriasis patients to gain a better understanding of their individual disease course and potential influencing factors. The interactive app can motivate patients and increase adherence to recommended behaviors and lifestyle changes for improved long-term patient outcomes. Additionally, patients will have the opportunity to share their health and disease progression data with their healthcare providers via an export function integrated into the app. With this voluntarily shared overview of the longitudinal progression of psoriasis, physicians can better monitor and adjust their patients' therapy.

This patient companion is the latest digital companion evolving from Temedica's app platform technology, which provides patient support on a new and personalized level. Temedica apps are characterized by the combination of medical expertise with a focus on patient safety and improved therapy outcomes. Temedica operates on an ISO 13485 certified quality management system and considers relevant international regulatory requirements when developing and operating digital patient offerings.

About Psoriasis

Psoriasis is a widely prevalent, chronic, systemic immune-mediated disease that substantially impairs patients' physical health, quality of life, and work productivity.^{1,2,3,4} Psoriasis is a serious global problem, with at least 100 million people worldwide impacted by some form of the disease, including around 14 million people in Europe and approximately 7.5 million people in the United States.^{5,6} Nearly one quarter of people with psoriasis have cases that are considered to be moderate to severe.⁷ Up to 90 % of patients with psoriasis have psoriasis vulgaris, or plaque psoriasis, which is characterized by distinct round or oval plaques typically covered by silvery-white scales.^{3,6,8,9,10,11} Despite the availability of effective systemic therapy, many patients with moderate to severe psoriasis remain undertreated or untreated and are dissatisfied with existing approaches.^{12,13} People with psoriasis report a negative impact on their emotional well-being, straining both personal and professional relationships and causing a reduced quality of life.^{14,15,16} Psoriasis is associated with multiple comorbidities that may impact patients' well-being, including psoriatic arthritis, cardiovascular disease, metabolic syndrome, obesity, diabetes, inflammatory bowel disease and depression.^{1,16,17}

About Temedica GmbH

Temedica is a Munich, Germany-based digital health and health insights company with the mission to bring the patient into the center of healthcare. The company develops state-of-the-art digital patient companions for complex, chronic conditions. These apps support patients with personalized guidance and help them navigate healthcare systems by considering their individual needs. Through direct and long-term interaction with patients, Temedica generates unique and previously unknown real-world evidence about disease progression and the individual effectiveness of therapies. Temedica has expertise in the personalized support of patients as well as in compiling, structuring, and analyzing respective health data. Its data analytics platform Permea is designed to enable unique insights along the entire healthcare value chain and patient journey. Temedica is supported by a consortium of renowned investors with longstanding track-records in the biopharmaceutical industry, including the founding investors of BioNTech. Further information is available at <https://temedica.com/en/>.

International Media and IR Contact

MC Services AG

Dr. Brigitte Keller, Katja Arnold

T +49 89 210228 0

UK: Shaun Brown

M: +44 7867 515 918

Email: temedica@mc-services.eu

Bristol-Myers Squibb GmbH & Co. KGaA

Eszter Viragh

Head of Corporate Affairs

T +49 89 12142 7036

E-mail: ca-germany@bms.com

References

- ¹ [WHO Global Report on Psoriasis: ISBN 978 92 4 156518 9 \(NLM classification: WR 205\)](#)
- ² Langley RGB et al. *Ann Rheum Dis.* 2005;64(Suppl II):ii18–ii23. <http://dx.doi.org/10.1136/ard.2004.033217>
- ³ Pariser D et al. *J Dermatolog Treat.* 2015;27(1):19-26. <https://doi.org/10.3109/09546634.2015.1044492>
- ⁴ Kimball AB et al. *J Eur Acad Dermatol Venereol.* 2010 Sep;24(9):989-1004. <https://doi.org/10.1111/j.1468-3083.2010.03705.x>
- ⁵ Menter A et al. *J Am Acad Dermatol.* 2008 May;58(5):826-50. <https://doi.org/10.1016/j.jaad.2008.02.039>
- ⁶ Ortonne JP et al. *Eur J Dermatol.* 2004 Jan-Feb;14(1):41-5. PMID: 14965795.
- ⁷ National Psoriasis Foundation. Psoriasis Statistics. <https://www.psoriasis.org/psoriasis-statistics/>. Accessed September 8, 2021.
- ⁸ Griffiths C et al. *Lancet.* 2007 Jul 21;370(9583):263-271. [https://doi.org/10.1016/S0140-6736\(07\)61128-3](https://doi.org/10.1016/S0140-6736(07)61128-3)
- ⁹ Alwan W et al. *Clin Exp Rheumatol.* Sep-Oct 2015;33(5 Suppl 93):S2-6. PMID: 26472336
- ¹⁰ Mahil S et al. *Semin Immunopathol.* 2016 Jan;38(1):11-27. <https://doi.org/10.1007/s00281-015-0539-8>
- ¹¹ Horn EJ et al. *J Am Acad Dermatol.* 2007;57:957-962. <https://doi.org/10.1016/j.jaad.2007.06.042>
- ¹² Armstrong A et al. *Dermatol Ther (Heidelb).* 2017 Mar; 7(1): 97–109. <https://doi.org/10.1007/s13555-016-0153-2>
- ¹³ Hrehorow, E et al. *Acta Derm Venereol.* 2012; 92(1):67-72. <https://doi.org/10.2340/00015555-1193>
- ¹⁴ Armstrong A et al. *Nutr Diabetes.* 2013. Dec 3;2(12):e54. <https://doi.org/10.1038/nutd.2012.26>
- ¹⁵ Dubertret L et al. *Br J Dermatol.* 2006 Oct;155(4):729-36. <https://doi.org/10.1111/j.1365-2133.2006.07405.x>
- ¹⁶ Oliveira M et al. *Anais brasileiros de dermatologia.* Jan-Feb2015; 90(1), 9–20. <https://doi.org/10.1590/abd1806-4841.20153038>
- ¹⁷ Neimann A et al. *J Am Acad Dermatol.* 2006;55(5), 829–835. <https://doi.org/10.1016/j.jaad.2006.08.040>